Humulin R (Insulin Human (Rdna))

Humulin R is indicated for the management of hyperglycemia in adults and children with diabetes mellitus. It is used to provide basal and mealtime insulin coverage in both type 1 and type 2 diabetes.

• Initiation of insulin therapy in newly diagnosed type 1 diabetes.
• Supplemental insulin for type 2 diabetes when oral agents are insufficient.
• Adjustment of insulin doses around meals to control post‑prandial glucose.
• Management of hyperglycemia during illness, stress, or steroid therapy.
• Use in insulin pump therapy as a rapid‑acting component.

• Humulin R delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑kinase/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface. This enhances glucose uptake, suppresses hepatic gluconeogenesis, and facilitates storage of glucose as glycogen, thereby lowering circulating blood glucose concentrations. The overall effect improves metabolic homeostasis and supports normal carbohydrate utilization.

Adverse reactions to Humulin R may vary in frequency and severity; they are typically categorized as common or serious.

Common

• Mild hypoglycemia, especially if meals are delayed or doses are high.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized fat loss or accumulation.
• Transient weight gain due to fluid retention.
• Nausea or mild abdominal discomfort.
• Headache or dizziness without hypoglycemia.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions ranging from urticaria to anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Edema or heart failure exacerbation in susceptible patients.
• Hypersensitivity leading to serum sickness‑like reaction.

When prescribing or using Humulin R, clinicians and patients should consider several precautionary measures to minimize risks and ensure optimal glycemic control.

• Adjust dose during periods of reduced food intake, increased physical activity, or illness.
• Monitor blood glucose frequently, especially when initiating therapy or changing dose.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Assess for signs of hypoglycemia in elderly or cognitively impaired individuals.
• Evaluate cardiovascular status, since rapid‑acting insulin can affect fluid balance.
• Avoid use during pregnancy unless benefits outweigh potential risks, and follow obstetric guidance.

Humulin R may interact with other medicines that affect glucose metabolism, insulin sensitivity, or cardiovascular function, requiring dose adjustments or monitoring.

Avoid

• Concurrent administration of other rapid‑acting insulins without appropriate dose reduction.
• Use with beta‑blockers in patients prone to hypoglycemia, as they may mask symptoms.
• Combination with high‑dose corticosteroids that markedly raise blood glucose.

Use with caution

• Sulfonylureas or meglitinides, which increase hypoglycemia risk.
• ACE inhibitors or ARBs in patients with renal impairment, as insulin clearance may change.
• Alcohol consumption, which can potentiate hypoglycemia, especially when meals are skipped.